An overview of current and emerging devices for percutaneous left atrial appendage closure

Danny H F Chow; Yam-Hong Wong; Jai-Wun Park; Yat-Yin Lam; Tom De Potter; Josep Rodés-Cabau; Lluis Asmarats; Marcus Sandri; Eleftherios Sideris; Trevor McCaw; Randall J Lee; Horst Sievert; Lars Søndergaard; Ole De Backer

doi:10.1016/j.tcm.2018.08.008

An overview of current and emerging devices for percutaneous left atrial appendage closure

Danny H F Chow, Yam-Hong Wong, Jai-Wun Park, Yat-Yin Lam, Tom De Potter, Josep Rodés-Cabau, Lluis Asmarats, Marcus Sandri, Eleftherios Sideris, Trevor McCaw, Randall J Lee, Horst Sievert, Lars Søndergaard, Ole De Backer

Research output: Contribution to journal › Review › Research › peer-review

18 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is common and is a prominent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy has been the main strategy for stroke prevention in AF patients; however, OAC therapy carries a bleeding risk and is not tolerated by all patients. Left atrial appendage (LAA) closure offers a non-pharmacological alternative for stroke prevention in patients with non-valvular AF. In this update, an overview of current and emerging LAA occluders is given - with special attention to the key design features of every single device and, if available, preclinical or clinical data.

Original language	English
Journal	Trends in Cardiovascular Medicine
Volume	29
Issue number	4
Pages (from-to)	228-236
ISSN	1050-1738
DOIs	https://doi.org/10.1016/j.tcm.2018.08.008
Publication status	Published - 2019

Keywords

Animals
Atrial Appendage/physiopathology
Atrial Fibrillation/complications
Cardiac Catheterization/adverse effects
Equipment Design
Humans
Risk Factors
Stroke/diagnosis
Treatment Outcome

Access to Document

10.1016/j.tcm.2018.08.008

Cite this

Chow, D. H. F., Wong, Y-H., Park, J-W., Lam, Y-Y., De Potter, T., Rodés-Cabau, J., Asmarats, L., Sandri, M., Sideris, E., McCaw, T., Lee, R. J., Sievert, H., Søndergaard, L., & De Backer, O. (2019). An overview of current and emerging devices for percutaneous left atrial appendage closure. Trends in Cardiovascular Medicine, 29(4), 228-236. https://doi.org/10.1016/j.tcm.2018.08.008

An overview of current and emerging devices for percutaneous left atrial appendage closure. / Chow, Danny H F; Wong, Yam-Hong; Park, Jai-Wun; Lam, Yat-Yin; De Potter, Tom; Rodés-Cabau, Josep; Asmarats, Lluis; Sandri, Marcus; Sideris, Eleftherios; McCaw, Trevor; Lee, Randall J; Sievert, Horst; Søndergaard, Lars; De Backer, Ole.

In: Trends in Cardiovascular Medicine, Vol. 29, No. 4, 2019, p. 228-236.

Research output: Contribution to journal › Review › Research › peer-review

Chow, DHF, Wong, Y-H, Park, J-W, Lam, Y-Y, De Potter, T, Rodés-Cabau, J, Asmarats, L, Sandri, M, Sideris, E, McCaw, T, Lee, RJ, Sievert, H, Søndergaard, L & De Backer, O 2019, 'An overview of current and emerging devices for percutaneous left atrial appendage closure', Trends in Cardiovascular Medicine, vol. 29, no. 4, pp. 228-236. https://doi.org/10.1016/j.tcm.2018.08.008

Chow, Danny H F ; Wong, Yam-Hong ; Park, Jai-Wun ; Lam, Yat-Yin ; De Potter, Tom ; Rodés-Cabau, Josep ; Asmarats, Lluis ; Sandri, Marcus ; Sideris, Eleftherios ; McCaw, Trevor ; Lee, Randall J ; Sievert, Horst ; Søndergaard, Lars ; De Backer, Ole. / An overview of current and emerging devices for percutaneous left atrial appendage closure. In: Trends in Cardiovascular Medicine. 2019 ; Vol. 29, No. 4. pp. 228-236.

@article{47d73046bd6e4354afd21d4440344aec,

title = "An overview of current and emerging devices for percutaneous left atrial appendage closure",

abstract = "Atrial fibrillation (AF) is common and is a prominent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy has been the main strategy for stroke prevention in AF patients; however, OAC therapy carries a bleeding risk and is not tolerated by all patients. Left atrial appendage (LAA) closure offers a non-pharmacological alternative for stroke prevention in patients with non-valvular AF. In this update, an overview of current and emerging LAA occluders is given - with special attention to the key design features of every single device and, if available, preclinical or clinical data.",

keywords = "Animals, Atrial Appendage/physiopathology, Atrial Fibrillation/complications, Cardiac Catheterization/adverse effects, Equipment Design, Humans, Risk Factors, Stroke/diagnosis, Treatment Outcome",

author = "Chow, {Danny H F} and Yam-Hong Wong and Jai-Wun Park and Yat-Yin Lam and {De Potter}, Tom and Josep Rod{\'e}s-Cabau and Lluis Asmarats and Marcus Sandri and Eleftherios Sideris and Trevor McCaw and Lee, {Randall J} and Horst Sievert and Lars S{\o}ndergaard and {De Backer}, Ole",

year = "2019",

doi = "10.1016/j.tcm.2018.08.008",

language = "English",

volume = "29",

pages = "228--236",

journal = "Trends in Cardiovascular Medicine",

issn = "1050-1738",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - An overview of current and emerging devices for percutaneous left atrial appendage closure

AU - Chow, Danny H F

AU - Wong, Yam-Hong

AU - Park, Jai-Wun

AU - Lam, Yat-Yin

AU - De Potter, Tom

AU - Rodés-Cabau, Josep

AU - Asmarats, Lluis

AU - Sandri, Marcus

AU - Sideris, Eleftherios

AU - McCaw, Trevor

AU - Lee, Randall J

AU - Sievert, Horst

AU - Søndergaard, Lars

AU - De Backer, Ole

PY - 2019

Y1 - 2019

N2 - Atrial fibrillation (AF) is common and is a prominent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy has been the main strategy for stroke prevention in AF patients; however, OAC therapy carries a bleeding risk and is not tolerated by all patients. Left atrial appendage (LAA) closure offers a non-pharmacological alternative for stroke prevention in patients with non-valvular AF. In this update, an overview of current and emerging LAA occluders is given - with special attention to the key design features of every single device and, if available, preclinical or clinical data.

AB - Atrial fibrillation (AF) is common and is a prominent risk factor for ischemic stroke. Oral anticoagulant (OAC) therapy has been the main strategy for stroke prevention in AF patients; however, OAC therapy carries a bleeding risk and is not tolerated by all patients. Left atrial appendage (LAA) closure offers a non-pharmacological alternative for stroke prevention in patients with non-valvular AF. In this update, an overview of current and emerging LAA occluders is given - with special attention to the key design features of every single device and, if available, preclinical or clinical data.

KW - Animals

KW - Atrial Appendage/physiopathology

KW - Atrial Fibrillation/complications

KW - Cardiac Catheterization/adverse effects

KW - Equipment Design

KW - Humans

KW - Risk Factors

KW - Stroke/diagnosis

KW - Treatment Outcome

U2 - 10.1016/j.tcm.2018.08.008

DO - 10.1016/j.tcm.2018.08.008

M3 - Review

C2 - 30205924

VL - 29

SP - 228

EP - 236

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 4

ER -